Geoffrey Kline

h-index

Research activity per year

If you made any changes in Pure these will be visible here soon.

Education/Academic qualification

BS in Biomedical Science, Texas A & M University

DO, UNT Health Science Center

PhD in Physiology, UNT Health Science Center

Fingerprint

Dive into the research topics where Geoffrey Kline is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

1 Similar Profiles

1 Active
6 Finished

A Long-term Outcomes Study to Assess Statin Residual Risk Reduction with EpaNova High Cardiovascular Risk Patients witgh Hypertriglyceridemia (STRENGTH)
Kline, G.
Astra Zeneca
8/06/15 → 30/06/24
Project: Research
A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with reduced Ejection Fraction (HFrEF).
Kline, G.
Boehringer Ingelheim International GmbH
25/04/17 → 24/04/21
Project: Research
A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fraction (HFpEF).
Kline, G.
Boehringer Ingelheim International GmbH
25/04/17 → 24/04/21
Project: Research
PROMINENT- PEMAFIBRATE TO REDUCE CARDIOVASCULAR OUTCOMES BY REDUCING TRIGLYCERIDES IN PATIENTS WITH DIABETES
Kline, G.
Kowa Research Institute, Inc.
31/03/17 → 31/03/21
Project: Research
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (ETC-I 002) on the Occurrence of Major Cardiovascular Events in Patients with, or at High Risk For,Cardiovascular Disease Who Are Statin Intolerant
Kline, G.
Esperion Therapeutics, Inc.
13/02/17 → 13/02/21
Project: Research

9 Article

Acute heat exposure protects against endothelial ischemia-reperfusion injury in aged humans
Hemingway, H. W., Richey, R. E., Moore, A. M., Olivencia-Yurvati, A. H., Kline, G. P. & Romero, S. A., May 2022, In: American Journal of Physiology - Regulatory Integrative and Comparative Physiology. 322, 5, p. R360-R367
Research output: Contribution to journal › Article › peer-review
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
ODYSSEY OUTCOMES Committees and Investigators, 3 Aug 2021, In: Journal of the American College of Cardiology. 78, 5, p. 421-433 13 p.
Research output: Contribution to journal › Article › peer-review

Open Access
15 Scopus citations
Intermittent Hypoxia Training for Treating Mild Cognitive Impairment: A Pilot Study
Wang, H., Shi, X., Schenck, H., Hall, J. R., Ross, S. E., Kline, G. P., Chen, S., Mallet, R. T. & Chen, P., 2020, In: American journal of Alzheimer's disease and other dementias. 35
Research output: Contribution to journal › Article › peer-review

Open Access
20 Scopus citations
Reduced cerebrovascular and cardioventilatory responses to intermittent hypoxia in elderly
Liu, X., Chen, X., Kline, G., Ross, S. E., Hall, J. R., Ding, Y., Mallet, R. T. & Shi, X., Jan 2020, In: Respiratory Physiology and Neurobiology. 271, 103306.
Research output: Contribution to journal › Article › peer-review
2 Scopus citations
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
ODYSSEY OUTCOMES Committees and Investigators, 1 Aug 2019, In: The Lancet Diabetes and Endocrinology. 7, 8, p. 618-628 11 p.
Research output: Contribution to journal › Article › peer-review
138 Scopus citations

Geoffrey Kline, DO, PhD

Personal profile

Education/Academic qualification

Fingerprint

Network

Dive into details

A Long-term Outcomes Study to Assess Statin Residual Risk Reduction with EpaNova High Cardiovascular Risk Patients witgh Hypertriglyceridemia (STRENGTH)

A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with reduced Ejection Fraction (HFrEF).

A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fraction (HFpEF).

PROMINENT- PEMAFIBRATE TO REDUCE CARDIOVASCULAR OUTCOMES BY REDUCING TRIGLYCERIDES IN PATIENTS WITH DIABETES

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (ETC-I 002) on the Occurrence of Major Cardiovascular Events in Patients with, or at High Risk For,Cardiovascular Disease Who Are Statin Intolerant

Acute heat exposure protects against endothelial ischemia-reperfusion injury in aged humans

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Intermittent Hypoxia Training for Treating Mild Cognitive Impairment: A Pilot Study

Reduced cerebrovascular and cardioventilatory responses to intermittent hypoxia in elderly

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Geoffrey Kline, DO, PhD

Personal profile

Education/Academic qualification

Fingerprint

Network

Projects

Research output